Skip to content

Progesterone and Cervical Pessary in Twins

Progesterone and Cervical Pessary in Twins : A Prospective and Randomized Study to Prevent Preterm Birth (PRECEPT)

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03058536
Acronym
PRECEPET
Enrollment
312
Registered
2017-02-23
Start date
2017-02-21
Completion date
2019-03-31
Last updated
2017-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth, Twin Pregnancy With Antenatal Problem

Keywords

twin short cervix pessary progesterone preterm birth

Brief summary

The aim of this randomized control trial is to determine wheter cervical pessary plus vaginal progesterone (400mg) reduce preterm birth less than 34 weeks of gestacion and improve perinatal outcome, among women presenting asyntomatic short cervix, in twin pregnancy.

Detailed description

The frequency of twin pregnancies has increased significantly, especially because of the assisted reproduction and advanced maternal age at conception. The twin pregnancies are responsible for 25 % of all preterm birth. Consequently, twin pregnancies are more associated with perinatal mortality and morbidity when compared to single pregnancies. Additionally, the short cervix (\< 25 mm) in singleton and twin pregnancies are associated with significantly increased preterm birth. Randomized controlled trials in singleton pregnancies reported that profilatic cervical cerclage and vaginal progesterone reduce significantly the rate of early preterm birth. In twin pregnancies, vaginal progesterone and profilatic cerclage have been shown to be ineffective in prevention of preterm birth. However, two individual pacient data meta-analyses reported in a subgroup of women with twin pregancies and short cervix, that vaginal progesterone reduce significantly adverse neonatal outcomes. Nowadays, the effet of cervical pessary is contraditory, mainly in women with short cervix. This is a randomized prospective trial at São Paulo University Medical School. This trial will involve 312 women with twins pregnancies and short cervix between 16 and 27 weeks and 6 days of gestacional age. Women with twin pregnancy and short cervix ( defined according to the gestacional age ) will be assigned randomly to daily vaginal progesterone (400mg) combined with insertion of cervical pessary, isolated use of daily vaginal progesterone (400mg) isolated insertion of cervical pessary or expectant management (no intervention). The primary outcome is to compare the rate of spontaneous delivery \< 34 weeks of gestacion between groups.The secondary outcome is to compare the neonatal adverse outcome between the groups. The aim of this study is to test the hypothesis that the insertion of a cervical pessary combined with vaginal progesterone, in twin pregnancies with short cervix would reduce the spontaneus preterm birth \< 34 weeks' gestation.

Interventions

The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.

DRUGVaginal Progesterone

Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.

OTHERArabin Pessary and Progesterone

Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.

Sponsors

Mario Henrique Burlacchini de Carvalho
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

312 twin pregnant women with short cervix between 16 and 27 weeks and 6 days of gestacional age will be randomized in four groups: daily 400mg vaginal progesterone combined with insertion of cervical pessary; isolated use of daily 400mg vaginal progesterone, isolated insertion of cervical pessary or expectant management (no intervention).

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Twin pregnancy ( dichorionic or monochorionic diamniotic) * Both fetuses alive * Asymptomatic short cervix according to gestational age ( measurement less or equal 30 mm between 16 weeks + 0 day and 22 weeks + 0 day, less or equal 25 mm between 22 weeks + 1 day and 24 weeks + 0 day and less or equal 20 mm between 24 weeks + 1 day and 27 weeks + 6 days) * Gestational age between 16 to 27weeks and 6 days * Intact membranes * Informed consent

Exclusion criteria

* Monoamniotic twins * Twin Twin transfusion syndrome * Rupture membranes * Major malformation or chromosomal abnormality at least one fetus * Women with Cervical cerclage in the current pregnancy * Ballooning of membranes outside the cervix into the vagina * Placenta previa * Treatment with progesterone before randomization * Allergy of the excipientes of the micronized progesterone * Labor * Severe hepatic disfunction, porphyria, otosclerosis, severe depression * Use of drugs that interfere the effects of progesterone

Design outcomes

Primary

MeasureTime frameDescription
Preterm birth5 monthsRate of preterm birth before 34 weeks gestation

Secondary

MeasureTime frameDescription
Neonatal Complications Ratebetween birth and 28 days of ageIncludes necrotizing enterocolitis, intraventricular hemorrhage (grade 3 or higher), respiratory distress syndrome, retinopathy, sepsis, use of mechanical ventilation, time of hospitalization, and neonatal death.
Months from Randomization to delivery interval6 monthsRandomization may begin at 16 weeks, and most patient will be delivered between 36 and 38 weeks gestation.

Countries

Brazil

Contacts

Primary ContactMario Henrique Burlacchini de Carvalho, PhD
mario.burlacchini@hc.fm.usp.br+55 11 26616209
Backup ContactCarolina Fiuza Branco
carolfiuzabranco@hotmail.com+55 11 986974207

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026